Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 95c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of $0.46, $0.95 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $126.3 million versus the consensus estimate of $50.49 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Fed: A Few Saw Case For Raising Rates At June Fomc Meeeting
• Vermilion Energy gets TSX approval to repurchase up to 10% of float